kr211.40
2.42% yesterday
Copenhagen, Oct 03, 05:00 pm CET
ISIN
DK0061802139
Symbol
ALK B

ALK-Abelló Stock price

kr211.40
+8.20 4.04% 1M
+69.00 48.46% 6M
+52.30 32.87% YTD
+44.40 26.59% 1Y
+89.90 73.99% 3Y
+101.00 91.49% 5Y
+172.55 444.14% 10Y
-788.60 78.86% 20Y
Copenhagen, Closing price Fri, Oct 03 2025
+5.00 2.42%
ISIN
DK0061802139
Symbol
ALK B
Industry

Key metrics

Basic
Market capitalization
kr45.9b
Enterprise Value
kr46.0b
Net debt
kr83.0m
Cash
kr509.0m
Shares outstanding
221.6m
Valuation (TTM | estimate)
P/E
46.2 | 37.5
P/S
7.8 | 7.1
EV/Sales
7.9 | 7.2
EV/FCF
657.6
P/B
7.9
Dividends
DPS
kr0.00
Yield 1Y | 5Y
0.0% | 0.0%
Growth 1Y | 5Y
- | -
Payout 1Y | 3Y
0.0% | 0.0%
Increased
0 Years
Financials (TTM | estimate)
Revenue
kr5.9b | kr6.4b
EBITDA
kr1.6b | kr1.9b
EBIT
kr1.4b | kr1.6b
Net Income
kr999.0m | kr1.2b
Free Cash Flow
kr70.0m
Growth (TTM | estimate)
Revenue
13.2% | 16.1%
EBITDA
39.1% | 64.9%
EBIT
47.1% | 47.1%
Net Income
44.8% | 53.2%
Free Cash Flow
-90.3%
Margin (TTM | estimate)
Gross
65.0%
EBITDA
28.0% | 30.2%
EBIT
23.1%
Net
17.0% | 19.4%
Free Cash Flow
1.2%
Financial Health
Equity Ratio
65.2%
Return on Equity
15.2%
ROCE
20.1%
ROIC
16.2%
Debt/Equity
0.1
More
EPS
kr4.6
FCF per Share
kr0.3
Short interest
-
Employees
3k
Rev per Employee
kr2.0m
Show more

Is ALK-Abelló a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,001 stocks worldwide.

ALK-Abelló Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a ALK-Abelló forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a ALK-Abelló forecast:

Buy
92%
Hold
8%

Financial data from ALK-Abelló

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
5,861 5,861
13% 13%
100%
- Direct Costs 2,054 2,054
8% 8%
35%
3,807 3,807
16% 16%
65%
- Selling and Administrative Expenses 1,901 1,901
5% 5%
32%
- Research and Development Expense 551 551
1% 1%
9%
1,640 1,640
39% 39%
28%
- Depreciation and Amortization 285 285
10% 10%
5%
EBIT (Operating Income) EBIT 1,355 1,355
47% 47%
23%
Net Profit 999 999
45% 45%
17%

In millions DKK.

Don't miss a Thing! We will send you all news about ALK-Abelló directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

ALK-Abello A/S engages in the production and development of pharmaceutical products to prevent and treat allergies. The firm manufactures tablet-based allergy vaccines for pollen, house dust mites, animals, and insect stings. Its treatment comprises allergy vaccines, emergency treatment, and allergy diagnostics. The company was founded by Poul Christian Krejner Tejn Barfod on June 9, 1923 and is headquartered in Horsholm, Denmark.

Head office Denmark
CEO Peter Halling
Employees 2,753
Founded 1923
Website www.alk.net

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today